REACTIVE OXYGEN-RELATED DISEASES: THERAPEUTIC TARGETS AND EMERGING CLINICAL INDICATIONS

Numerous diseases and disease models have been suggested to be associated with oxidative stress; however very few if any have resulted in clinical application; some trials have been giant failures. Two innovations may provide a more successful and evidence-based way forward: the therapeutic move from focussing on ROS to their enzymatic sources and targets and the differentiation of physiological and pathological functions of these. Moreover a cluster of disease phenotypes within the so-called ‘diseasesome’ seems specifically linked to ROS- mediate pathologies. Here we present examples for such target validation within this cluster in diabetic end-organ damage and stroke, both linked by shared common redox mechanisms. These therapeutic advances will be backed-up by precision diagnostics that enable early detection, patient stratification, detecting target engagement and therapeutic monitoring.